Fig. 2
From: CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer
a. At D-1, MSC are plated on a transwell and OCCs on a well itself. At D0, MSC and OCCs are put in contact (control and removed) or not (Ă˜ incubation) with the OCCs. At D2, MSC are kept on OCCs (control), or added to OCCs (Ă˜ incubation) or removed from OCCs (removed) and the chemotherapy (100 μM carboplatin, 0.1 μM Taxol) is added for 24 h. At D3, cells were harvested. b. OCCs were treated with Carboplatin (100 μM) and Taxol (0.1 μM) for 24 h. Prior to the treatment OCCs were either culture alone (control) or 48 h with MSC (Removed). At the moment of the chemotherapy treatment MSC were removed or added to assess the role of the MSC incubation (Ă˜ incubation). Histograms represent the percentage of living cells compared to the untreated cells. Mean (±SEM) of 3 different experiments. p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***). c. OCCs were incubated or not with IL-6 (50 ng/ml) for 48 h following by chemotherapy treatment of Carboplatin (100 μM) and Taxol (0.1 μM) for 24 h. OCCs were harvested and stained with PI and Annexin V. The gates had been drawn as in B for each conditions on the plot. d. OCCs alone or in transwell with MSC (Trans) were incubated or not with a blocking antibody against IL-6 (20 μg/mL) for 48 h following by chemotherapy treatment of Carboplatin (200 μM) and Taxol (0.1 μM) for 24 h. OCCs were harvested and stained with PI and Annexin V. The gates had been drawn as in B for each conditions on the plot. p < 0.05 (*), p < 0.01 (**) or p < 0.001 (***)